{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:56Z","timestamp":1785560276841,"version":"3.56.0"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.2169\/internalmedicine.6289-25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T22:08:36Z","timestamp":1767305316000},"page":"2136-2141","source":"Crossref","is-referenced-by-count":0,"title":["An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression"],"prefix":"10.2169","volume":"65","author":[{"given":"Yoko","family":"Nakanishi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"},{"name":"Department of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Nishitarumizu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Aichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokkaichi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Sanda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Nanri","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384: 705-716, 2021.","DOI":"10.1056\/NEJMoa2024850"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144: 2389-2401, 2024.","DOI":"10.1182\/blood.2024024582"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388: 1002-1014, 2023.","DOI":"10.1056\/NEJMoa2213614"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Delforge M, Vekemans MC, Depaus J, et al. Ciltacabtagene autoleucel for patients with triple-class exposed multiple myeloma: adjusted comparison of CARTITUDE-1 patient outcomes versus real-world clinical practice. Hemasphere 6: e813, 2022.","DOI":"10.1097\/HS9.0000000000000813"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol 41: 2087-2097, 2023.","DOI":"10.1200\/JCO.22.01365"},{"key":"6","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.bneo.2024.100051","volume":"2","author":"T Jo","year":"2024","unstructured":"6. Jo T, Yoshihara S, Okuyama Y, et al. Low platelet counts and low CD4\/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma. Blood Neoplasia 2: 100051, 2024.","journal-title":"Blood Neoplasia","ISSN":"https:\/\/id.crossref.org\/issn\/2950-3280","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. W\u00e5linder G, Samuelsson J, N\u00e4sman P, et al. Outcome and characteristics of non-measurable myeloma: a cohort study with population-based data from the Swedish myeloma registry. Eur J Haematol 104: 376-382, 2020.","DOI":"10.1111\/ejh.13351"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J; Chinese Medical Doctor Association Hematology Branch. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J 4: e239, 2014.","DOI":"10.1038\/bcj.2014.55"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takamatsu H, Yamashita T, Kurahashi S, et al. Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 25: 474-479, 2019.","DOI":"10.1016\/j.bbmt.2018.11.003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33: 2266-2275, 2019.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood Cancer Discov 6: 38-54, 2024.","DOI":"10.1158\/2643-3230.BCD-24-0118"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6289-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:13:53Z","timestamp":1785557633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6289-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":11,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6289-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"6289-25"}}